Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Earic Bonner

Internal Medicine Edenton, NC Medical Doctor

NPI 1548526411 CMS profile 1380343

105 Mark Dr, Edenton, NC 27932

Open in the dashboard

General payments

$7,823

412 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Earic Bonner of Edenton, NC is reported in the CMS Open Payments database as having received $7,823 across 412 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $184 10
2024 General $554 32
2023 General $938 55
2022 General $1,204 76
2021 General $1,007 61
2020 General $2,577 94
2019 General $1,359 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Earic Bonner
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Earic Bonner were reported at $184. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Earic Bonner Internal Medicine median Middle half National median
2019 $1,359 $159 $48–$570 $163
2020 $2,577 $119 $33–$402 $114
2021 $1,007 $135 $37–$521 $132
2022 $1,204 $141 $42–$496 $149
2023 $938 $149 $45–$519 $160
2024 $554 $154 $47–$537 $164
2025 $184 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,823 31 payments
  2. Novo Nordisk Inc $1,323 102 payments
  3. Sanofi-Aventis U.S. LLC $764 47 payments
  4. Lilly USA, LLC $659 37 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $577 33 payments
  6. Amgen Inc. $403 21 payments
  7. Novartis Pharmaceuticals Corporation $304 20 payments
  8. Pfizer Inc. $283 17 payments
  9. Janssen Pharmaceuticals, Inc $254 22 payments
  10. Merck Sharp & Dohme Corporation $234 17 payments
  11. Other $1,200 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,563 411 payments
  2. Consulting Fee $1,260 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $1,744 26 payments
  2. Ozempic $905 67 payments
  3. RYBELSUS $752 54 payments
  4. Repatha $392 20 payments
  5. JARDIANCE Diabetes $377 21 payments
  6. JARDIANCE Diabetes $346 21 payments
  7. TRULICITY $291 16 payments
  8. XARELTO $254 22 payments
  9. SOLIQUA 100/33 Endocrine & Metabolic Diseases $237 16 payments
  10. SOLIQUA 100/33 Diabetes $226 14 payments
  11. Other $5,014 322 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 163 drugs

Part D claims

12,708

Median for Internal Medicine: 777

Drug cost

$1,378,156

Median for Internal Medicine: $73,373

Branded share of claims

23%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 151 $131,255
Xarelto Rivaroxaban Brand 159 $124,266
Ozempic Semaglutide Brand 70 $111,248
Januvia Sitagliptin Phosphate Brand 94 $76,864
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 79 $74,604
Jardiance Empagliflozin Brand 66 $60,786
Tradjenta Linagliptin Brand 57 $58,500
Tresiba Flextouch U-100 Insulin Degludec Brand 106 $50,070
Trulicity Dulaglutide Brand 47 $48,811
Rybelsus Semaglutide Brand 27 $47,022

The 10 drugs with the highest cost, of 163 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$195,189

Of which drugs: $63,495

Medicare patients

349

Average age 76

Services billed

5,210

168 women, 181 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 40%
Arthritis 37%
Chronic kidney disease 24%
Ischemic heart disease 23%
Atrial fibrillation 21%
Heart failure 15%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 143 163 $24,150
Vaccine for influenza for injection into muscle 90662 Office 175 175 $12,355
Pcv20 vaccine im 90677 Office 17 17 $4,919

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $93
  • Lilly USA, LLC $51
$144 66 —
RYBELSUS
  • Novo Nordisk Inc $73
$73 27 —
Ozempic
  • Novo Nordisk Inc $73
$73 70 —
ZEPBOUND
  • Lilly USA, LLC $53
$53 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

412 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record